Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 192

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Prognostic and predictive value of tumor-infiltrating lymphocytes for clinical therapeutic research in patients with non-small cell lung cancer

Open access
Zeng, Dong-Qiang, Yu, Yun-Fang, Ou, Qi-Yun, Li, Xiao-Yin, Zhong, Ru-Zhi, Xie, Chuan-Miao, Hu, Qiu-Gen · 2016 · Oncotarget

Abstract

// Dong-Qiang Zeng 1, 2, * , Yun-Fang Yu 1, * , Qi-Yun Ou 3, 4, * , Xiao-Yin Li 5 , Ru-Zhi Zhong 6 , Chuan-Miao Xie 4 , Qiu-Gen Hu 1 1 Department of Radiology, Affiliated Shunde First People’s Hospital of Southern Medical University, Foshan, Guangdong, P. R. China 2 School of Basic Medical Sciences, Southern Medical University, Guangzhou, Guangdong, P. R. China 3 Department of Ultrasound, Affiliated Shunde First People’s Hospital of Southern Medical University, Foshan, Guangdong, P. R. China 4 Imaging Diagnostic and Interventional Center, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, P. R. China 5 Department of Medical Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, P. R. China 6 Guangdong Agricultural Reclamation Central Hospital, Affiliated Zhanjiang Cancer Hospital of Guangdong Medical University, Zhanjiang, Guangdong, P. R. China * These authors have contributed equally to this work and were co-first authors Correspondence to: Qiu-Gen Hu, e-mail: hqiugen@126.com Chuan-Miao Xie, e-mail: xchuanm@126.com Keywords: meta-analysis, molecular subtypes, non-small cell lung cancer, survival, tumor-infiltrating lymphocytes Received: November 09, 2015 Accepted: January 28, 2016 Published: February 09, 2016 ABSTRACT Background: Previous preclinical and clinical studies have shown that levels of tumor-infiltrating lymphocytes (TILs) significantly correlated with prognosis in non-small cell lung cancer (NSCLC), and survival after therapy; however, this finding remains controversial. We performed a meta-analysis, to evaluate, systematically, the clinical utilization of TIL subtypes in patients with NSCLC. Methods: The PubMed, ISI Web of Science, EMBASE, and Cochrane Library databases were searched to identify relevant studies. We pooled estimates of treatment effects, and hazards were summarized using random or fixed effects models to evaluate survival outcomes. Results: A total of 24 relevant studies involving 7,006 patients were eligible. The median percentage of lymph node positivity was 45.7% (95% confidence interval [CI], 37.1–56.4%). Pooled analysis shows that high levels of CD8 + TILs had a good prognostic effect on survival with a hazard ratio (HR) of 0.91 ( P = 0.013) for death and 0.74 ( P = 0.001) for recurrence, as did high levels of CD3 + and CD4 + TILs, with HRs of 0.77 ( P = 0.009) and 0.78 ( P = 0.005) for death, respectively. By contrast, high levels of FoxP3 + regulatory TILs had a worse prognostic effect for overall and recurrence-free survival, with HRs of 1.69 ( P = 0.042) and 1.79 ( P = 0.001), respectively. No individual study affected the results, and no publication bias was found. Conclusions: Our findings support the hypothesis that TILs could be a prognostic marker in NSCLC. High-quality randomized studies are needed to verify statistically the effect of TILs on prognosis in future research.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.7282

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 192

Metadata

Authors
Zeng, D.-Q., Yu, Y.-F., Ou, Q.-Y., Li, X.-Y., Zhong, R.-Z., Xie, C.-M., & Hu, Q.-G.
Venue
Oncotarget
Published
2016-02-09
Volume
7
Issue
12
Pages
13765-13781
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2302719382
Cited by
192
References
10
FWCI
9.12
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.